Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2021 07:30 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes

BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that it will be...
September 08, 2021 07:30 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Markus...
August 12, 2021 07:30 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

– Completed upsized $255.6 million IPO; cash runway extended into late 2024 – Continued advancement of QuEEN™ protein degradation platform and pipeline of molecular glue degraders, including NEK7...
June 23, 2021 20:20 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the...